Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023
Pipeline prioritization extends anticipated cash runway into 2025
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2023 as well as certain other business highlights.
“In the first quarter, we prioritized our diabetes program, SIG-002, which we are advancing with Eli Lilly and Company. With Lilly reimbursing us for the costs of our diabetes research and development activities, we are able to advance IND-enabling activities for SIG-002, including non-human primate studies, that we expect to initiate in the second half of this year,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “I am truly excited about the progress our team has made over the past five years in collaboration with Lilly; this includes successfully differentiating induced pluripotent stem cells into mixed populations of cell types approximating human islet cells, and importantly, improving the stability and integrity of our spheres to encapsulate these cells. Additionally, with an expected IND submission for SIG-002 in 2024, we have extended our anticipated cash runway into 2025.”
Added Sarah Yuan, Ph.D., the Company’s Chief Technical Operations Officer: “As we advance our diabetes program toward the clinic, this quarter we welcomed Dr. Ying Jing as our new incoming VP of Process Development. Dr. Jing brings nearly two decades of industry expertise, including experience with the development and scale up of biomanufacturing processes to support clinical trials. We look forward to her contributions as we advance our diabetes program toward the clinic.”
Recent Program Highlights and Anticipated Milestones
- Sigilon’s near-term focus is on development efforts for SIG-002, its product candidate for type 1 diabetes, which is being developed in collaboration with Eli Lilly and Company. Sigilon initiated IND-enabling activities for SIG-002, including process development activities and in vivo studies and anticipates initiating non-human primate (NHP) studies in the second half of this year.
- The Company recently incorporated several important changes into its SLTx platform designed to mitigate immune responses to its product candidates resulting in pericapsular fibrotic overgrowth (PFO). In addition, using an innovative high-throughput in vitro macrophage attachment assay developed by the Company to rapidly evaluate the potential PFO response to allogeneic cell products together with preclinical studies in more than 700 humanized mice designed to recapitulate PFO, the Company has continued to improve its SLTx platform and generate in vitro and in vivo data. All of these platform optimizations have been incorporated into SIG-002 and will be used to support the continued development of the current and future product candidates.
- In the first quarter of 2023, Sigilon decreased its external spend relating to the mucopolysaccharidosis type 1 (MPS-1) program to preserve capital. For MPS-1 and other lysosomal disorders, Sigilon remains focused on engineering techniques and other cell line strategies that could limit or otherwise avoid a patient’s immune response to the Company’s product candidates, as well as optimize blood-brain barrier penetration and product half-life.
Corporate Updates
- Ying Jing, Ph.D., recently joined the Company as the new VP of Process Development. Dr. Jing has more than 17 years of industry experience in developing innovative, scalable, productive, and robust biomanufacturing processes to support clinical trials and commercial supply of biotherapeutics for patients. Most recently, Dr. Jing worked at 2seventy bio—the oncology spinoff of bluebird bio—as a Sr. Director of Process Science.
Financial Results
- Cash Position: Cash, cash equivalents and marketable securities were
$56.4 million as of March 31, 2023 compared to$69.6 million as of December 31, 2022. The decrease was primarily driven by cash used in operating activities and scheduled principal payments on the Company’s debt. The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to support its currently anticipated operating expenses and capital expenditure requirements into 2025.
- R&D Expenses: Research and development expenses were
$7.8 million for the first quarter of 2023 compared to$11.6 million for the first quarter of 2022. The decrease in research and development expenses was primarily due to the Company’s decrease in external spend relating to the MPS-1 program to preserve capital and the close out of the clinical trial for hemophilia A. This decrease was partially offset by increased activities related to the diabetes program.
- G&A Expenses: General and administrative expenses were
$4.3 million for the first quarter of 2023 compared to$5.0 million for the first quarter of 2022. The decrease in general and administrative expenses is due to decreased insurance-related costs related to operating as a publicly traded company.
- Net Loss: Net loss was
$7.4 million for the first quarter of 2023 compared to$13.9 million for the first quarter of 2022. The decrease was primarily due to savings in Sigilon’s operating expenses from its updated strategy and increased collaboration revenue associated with Sigilon’s collaboration with Eli Lilly and Company.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce a wide range of functions or therapeutic molecules that may be missing or deficient in patients living with diseases such as diabetes. The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, which is designed to shield them from immune rejection. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the initiation and timing of IND-enabling activities and non-human primate studies for SIG-002, our plan to submit an IND for SIG-002in 2024 and advance our diabetes program into the clinic, and our expected cash runway. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that if we cannot comply with Nasdaq’s continued listing standards, our common stock could be delisted; if negative results of preclinical or clinical studies of any of our product candidates could adversely affect our business and may require us to discontinue or delay development of other product candidates, which are all based on the same SLTx platform; the SLTx platform consists of novel technologies that are not yet clinically validated for human therapeutic use and the approaches we are taking to discover and develop novel therapeutics are unproven; we may not be successful in our efforts to identify and develop product candidates; if clinical trials of our current and future product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates; if we are unable to obtain and maintain patent and other intellectual property protection our product candidates, our SLTx platform may be adversely affected, and the risks identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (the “SEC”), as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
| Sigilon Therapeutics, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited, in thousands, except share and per share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 41,255 | $ | 42,066 | ||||
| Marketable securities | 15,114 | 27,560 | ||||||
| Accounts receivable | 3,162 | 2,171 | ||||||
| Unbilled accounts receivable | 1,798 | 1,287 | ||||||
| Prepaid expenses and other current assets | 3,067 | 1,077 | ||||||
| Restricted cash, current portion | 251 | 250 | ||||||
| Total current assets | 64,647 | 74,411 | ||||||
| Property and equipment, net | 2,872 | 2,854 | ||||||
| Right‑of‑use assets | 8,031 | 8,979 | ||||||
| Restricted cash | 1,038 | 1,034 | ||||||
| Total assets | $ | 76,588 | $ | 87,278 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,331 | $ | 936 | ||||
| Accrued expenses and other current liabilities | 3,506 | 6,021 | ||||||
| Lease liabilities, current portion | 4,498 | 4,485 | ||||||
| Current portion of long‑term debt | 6,667 | 6,667 | ||||||
| Deferred revenue from related party, current portion | 12,987 | 12,885 | ||||||
| Total current liabilities | 28,989 | 30,994 | ||||||
| Lease liability, net of current portion | 3,892 | 4,888 | ||||||
| Long‑term debt, net of discount and current portion | 10,413 | 12,021 | ||||||
| Other liabilities | — | 233 | ||||||
| Total liabilities | 43,294 | 48,136 | ||||||
| Stockholders’ equity | ||||||||
| Common stock, par value | 32 | 32 | ||||||
| Preferred stock, par value | — | — | ||||||
| Additional paid‑in capital | 297,713 | 296,339 | ||||||
| Accumulated other comprehensive loss | (273 | ) | (429 | ) | ||||
| Accumulated deficit | (264,178 | ) | (256,800 | ) | ||||
| Total stockholders’ equity | 33,294 | 39,142 | ||||||
| Total liabilities and stockholders’ equity | $ | 76,588 | $ | 87,278 | ||||
| Sigilon Therapeutics, Inc. | ||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (Unaudited, in thousands, except share and per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | ||||||||
| Collaboration revenue | $ | 4,858 | $ | 3,165 | ||||
| Operating expenses: | ||||||||
| Research and development | 7,782 | 11,618 | ||||||
| General and administrative | 4,323 | 5,024 | ||||||
| Total operating expenses | 12,105 | 16,642 | ||||||
| Loss from operations | (7,247 | ) | (13,477 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest income | 476 | 64 | ||||||
| Interest expense | (611 | ) | (491 | ) | ||||
| Other income, net | 4 | 45 | ||||||
| Total other income (expense), net | (131 | ) | (382 | ) | ||||
| Net loss attributable to ordinary shareholders | $ | (7,378 | ) | $ | (13,859 | ) | ||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.23 | ) | $ | (0.43 | ) | ||
| Weighted average common stock outstanding—basic and diluted | 32,467,382 | 32,360,786 | ||||||
SOURCE: Sigilon Therapeutics, Inc.
Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837
Media Contacts
Amy Bonanno
Solebury Strategic Communications
abonanno@soleburystrat.com
914-450-0349
